Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-CD20 Monoclonal Antibody”

102 trials

Showing 20 of 102 results

Early research (Phase 1)Study completedNCT04599634
What this trial is testing

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma+2 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Study completedNCT00346684
What this trial is testing

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Who this might be right for
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
University of Cologne
Testing effectiveness (Phase 2)Ended earlyNCT00072449
What this trial is testing

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Who this might be right for
Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT07480863
What this trial is testing

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Who this might be right for
Marginal Zone Lymphoma(MZL)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 65
Large-scale testing (Phase 3)Study completedNCT00004179
What this trial is testing

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC 475
Early research (Phase 1)Looking for participantsNCT05668403
What this trial is testing

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Who this might be right for
Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd 52
Large-scale testing (Phase 3)Looking for participantsNCT06284122
What this trial is testing

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Who this might be right for
Follicular Lymphoma
The Lymphoma Academic Research Organisation 790
Testing effectiveness (Phase 2)Study completedNCT06894940
What this trial is testing

Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies

Who this might be right for
Multiple Sclerosis
University of Pavia 82
Testing effectiveness (Phase 2)WithdrawnNCT00004039
What this trial is testing

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Ended earlyNCT01390545
What this trial is testing

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis
Takeda 300
Post-approval studies (Phase 4)Study completedNCT01280682
What this trial is testing

Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes

Who this might be right for
Type 1 Diabetes
Yang Tao 120
Large-scale testing (Phase 3)UnknownNCT02772822
What this trial is testing

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Who this might be right for
Diffuse Large B Cell Lymphoma
Sinocelltech Ltd. 330
Testing effectiveness (Phase 2)Study completedNCT00003397
What this trial is testing

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Maryland, Baltimore 25
Testing effectiveness (Phase 2)Looking for participantsNCT05995054
What this trial is testing

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Who this might be right for
Immune ThrombocytopeniaTreatment
Institute of Hematology & Blood Diseases Hospital, China 110
Testing effectiveness (Phase 2)Looking for participantsNCT06094881
What this trial is testing

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Who this might be right for
Immune ThrombocytopeniaTreatment
Institute of Hematology & Blood Diseases Hospital, China 60
Large-scale testing (Phase 3)Study completedNCT02867566
What this trial is testing

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Who this might be right for
Diffuse, Large B-Cell, Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 420
Testing effectiveness (Phase 2)Study completedNCT04083014
What this trial is testing

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Who this might be right for
Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
Peking Union Medical College Hospital 33
Testing effectiveness (Phase 2)Study completedNCT00695409
What this trial is testing

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 122
Testing effectiveness (Phase 2)UnknownNCT03332888
What this trial is testing

Safety of HMA-CD20 in Patients With HFrEF

Who this might be right for
Heart Failure With Reduced Ejection Fraction
Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud 10
Early research (Phase 1)Ended earlyNCT04245722
What this trial is testing

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Who this might be right for
Lymphoma, B-CellChronic Lymphocytic Leukemia
Fate Therapeutics 98
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation